• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients.

作者信息

Pou L, Brunet M, Andres I, Rodamilans M, Lopez R, Corbella J

机构信息

Biochemistry Service, Hospital General Vall d'Hebron, University of Barcelona, Spain.

出版信息

Transpl Int. 1998;11 Suppl 1:S270-1. doi: 10.1007/s001470050476.

DOI:10.1007/s001470050476
PMID:9664994
Abstract

The dosage of tacrolimus (D), the trough blood concentrations (C) and the evolution of the D/C ratio were followed for 1 year after transplantation in so adult patients (38 males and 12 females) undergoing liver allograft. A total of 1489 samples were analysed by the IMx tacrolimus method. The overall median concentration was 11.27 ng/ml. During the 1st month the median of the tacrolimus levels was 8.4 ng/ml, and 73.1% of the analysed samples were within the established therapeutic range. The median oral tacrolimus dose was progressively reduced from 0.12 mg/kg per day during the 1st month to 0.06 mg/kg per day at the end of studied period. A significant negative association was observed between the D/C ratio and the post-transplantation period (r = -0.3892; P < 0.0001). The median D/C ratio ranged from 0.0144 at 1st month to 0.0053 at 1 year. Significant D/C declines were observed after the 1st and 3rd months posttransplant. The decrease in corticosteroid doses and the increase in serum albumin may explain the reduction in clearance with time.

摘要

相似文献

1
Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients.
Transpl Int. 1998;11 Suppl 1:S270-1. doi: 10.1007/s001470050476.
2
Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up.肝移植中环孢素A的治疗药物监测,III期FK506多中心西班牙研究组:两年随访
Ther Drug Monit. 1998 Dec;20(6):602-6. doi: 10.1097/00007691-199812000-00003.
3
Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.亚洲肝移植患者全血和血浆中他克莫司的群体药代动力学
Clin Pharmacokinet. 2006;45(1):59-75. doi: 10.2165/00003088-200645010-00004.
4
Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study.经舌下途径给予他克莫司,在肝移植中采用较低剂量可提供与口服途径相似的药物暴露:一项初步研究。
Aliment Pharmacol Ther. 2017 May;45(9):1225-1231. doi: 10.1111/apt.14022. Epub 2017 Mar 6.
5
FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.FK506治疗难治性肾移植排斥反应:来自肝移植的经验教训。
Clin Transplant. 1996 Aug;10(4):323-32.
6
Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.CYP3A5基因多态性对肾移植受者他克莫司剂量需求及谷浓度的动态影响。
J Clin Pharm Ther. 2017 Feb;42(1):93-97. doi: 10.1111/jcpt.12480. Epub 2016 Nov 25.
7
Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients.成人肝移植受者口服与舌下含服他克莫司的临床药代动力学
Exp Clin Transplant. 2012 Dec;10(6):586-91. doi: 10.6002/ect.2012.0032. Epub 2012 Jul 5.
8
Weight-based tacrolimus trough concentrations post liver transplant.肝移植后基于体重的他克莫司谷浓度。
Intern Med J. 2019 Jan;49(1):79-83. doi: 10.1111/imj.14043.
9
Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients.监测肝移植患者他克莫司血药浓度的临床效用。
J Clin Pharmacol. 2001 May;41(5):542-51. doi: 10.1177/00912700122010429.
10
Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.胰腺移植受者中克霉唑与他克莫司之间具有临床意义的药物相互作用及同种异体移植排斥反应的相关风险。
Pharmacotherapy. 2016 Mar;36(3):335-41. doi: 10.1002/phar.1718. Epub 2016 Mar 11.

引用本文的文献

1
Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies.CYP3A4*22 和 POR*28 变异对肾移植受者他克莫司药代动力学的影响:18 项观察性研究的荟萃分析。
BMC Nephrol. 2024 Feb 6;25(1):48. doi: 10.1186/s12882-024-03467-4.
2
Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: A comparison of Michaelis-Menten and theory-based pharmacokinetic models.肝移植术后早期成年受者他克莫司的前瞻性群体药代动力学研究:米氏方程和基于理论的药代动力学模型比较
Front Pharmacol. 2022 Nov 9;13:1031969. doi: 10.3389/fphar.2022.1031969. eCollection 2022.
3
Identification of peripheral CD154 T cells and HLA-DRB1 as biomarkers of acute cellular rejection in adult liver transplant recipients.
鉴定外周血 CD154T 细胞和 HLA-DRB1 作为成人肝移植受者急性细胞排斥反应的生物标志物。
Clin Exp Immunol. 2021 Feb;203(2):315-328. doi: 10.1111/cei.13533. Epub 2020 Oct 29.
4
Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.在异基因造血干细胞移植受者中,马拉维若与他克莫司之间不存在显著的药代动力学相互作用。
J Antimicrob Chemother. 2015 Jul;70(7):2078-83. doi: 10.1093/jac/dkv082. Epub 2015 Apr 16.
5
Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.儿童肝移植患者中他克莫司的群体药代动力学和药物遗传学分析。
Br J Clin Pharmacol. 2014 Jan;77(1):130-40. doi: 10.1111/bcp.12174.
6
Dosing equation for tacrolimus using genetic variants and clinical factors.基于遗传变异和临床因素的他克莫司剂量方程。
Br J Clin Pharmacol. 2011 Dec;72(6):948-57. doi: 10.1111/j.1365-2125.2011.04039.x.
7
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.在ANRS HC - 08研究中,高效抗逆转录病毒疗法对丙型肝炎病毒和人类免疫缺陷病毒合并感染的肝移植受者中他克莫司药代动力学的影响。
Clin Pharmacokinet. 2007;46(11):941-52. doi: 10.2165/00003088-200746110-00002.
8
Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.肾移植患者中他克莫司的群体药代动力学和生物利用度
Br J Clin Pharmacol. 2007 Dec;64(6):750-7. doi: 10.1111/j.1365-2125.2007.02895.x. Epub 2007 Apr 10.
9
Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.他克莫司在全肝移植患者中的群体药代动力学:术后清除率建模
Eur J Clin Pharmacol. 2005 Jul;61(5-6):409-16. doi: 10.1007/s00228-005-0933-6. Epub 2005 Jul 1.
10
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.他克莫司在实体器官移植中的临床药代动力学与药效学
Clin Pharmacokinet. 2004;43(10):623-53. doi: 10.2165/00003088-200443100-00001.